Telephus Biosciences Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $6M
Latest Deal Amount
  • Investors
  • 4

Telephus Biosciences General Information

Description

Developer of monoclonal antibody designed for antibiotic-resistant staph infections. The company's antibody is based on TPH 101, a humanized monoclonal antibody, to prevent staphylococcus reinfection and accompanying osteomyelitis in patients receiving total hip arthroplasty (THA) or total knee arthroplasty (TKA) septic revision surgery, enabling the native immune response to clear the infection and improve safety by reducing antibiotic drug interactions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 12707 High Bluff Drive
  • Suite 200
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Telephus Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Grant 16-Nov-2017 $6M 00.00 Completed Generating Revenue
2. Early Stage VC 01-Feb-2017 00.00 Completed Generating Revenue
1. Early Stage VC (Series A) 15-Apr-2013 $1.4M $1.4M Completed Generating Revenue
To view Telephus Biosciences’s complete valuation and funding history, request access »

Telephus Biosciences Executive Team (10)

Name Title Board Seat Contact Info
Steve Zaniboni Chief Financial Officer
Caryn Peterson Executive, Regulatory Affairs
Edward Schwarz Ph.D Co-Founder and Chief Scientific Advisor
David Leve JD Board Manager
Robert Geckeler Vice President, Operations
You’re viewing 5 of 10 executive team members. Get the full list »

Telephus Biosciences Board Members (4)

Name Representing Role Since
Antonius Schuh Ph.D Telephus Biosciences Executive Chairman 000 0000
Mike Maloney MD Telephus Biosciences Board Manager 000 0000
Seth Zeidman MD Telephus Biosciences Board Manager 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Telephus Biosciences Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
Global Source Ventures Venture Capital Minority 000 0000 000000 0
UR Ventures Corporate Venture Capital Minority 000 0000 000000 0
WS Investments Corporate Venture Capital Minority 000 0000 000000 0
To view Telephus Biosciences’s complete investors history, request access »